Capmatinib Drug Encyclopedia

Capmatinib is an innovative targeted therapy drug used to treat non-small cell lung cancer (NSCLC). This drug was developed to address the abnormal expression or overactivation of MET (tyrosine kinase) in some patients with lung cancer. MET is a protein involved in regulating cell growth, differentiation and migration. In some cancers, abnormal activation of the MET pathway may lead to abnormal proliferation and spread of cancer cells.

Capmatinib selectively inhibits the activity ofMETkinase, thereby blocking abnormal cell signaling and inhibiting the growth and spread of lung cancer. This innovative treatment method makes capmatinib a targeted drug, especially suitable for patients with NSCLC whose MET gene is mutated or overexpressed.

Capmatinib is usually given as an oral medication that can be administered at home. This drug has shown significant efficacy in clinical trials, especially in patients with MET-driven non-small cell lung cancer, bringing new treatment hope. However, like all drugs, capmatinib may be accompanied by a series of side effects, including but not limited to fatigue, nausea, high blood pressure, etc. Therefore, patients need to closely cooperate with their doctors during use and receive regular medical monitoring.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.